Dear Members of the Englander Institute,
I recently Chaired a very interesting and engaging National Cancer Institute workshop, part of the Biden Cancer Moonshot initiative, called "Using AI Approaches to Target Undruggable Cancer Targets." You can view the workshop in its entirety here. 
Congratulations to the inaugural Bridge2AI Voice Summer School class! Students spent the summer with co-program leader Dr. Anaïs Rameau from WCM's Sean Parker Institute for the Voice and EIPM faculty conducting independent research and presented to their cohort, participating Bridge2AI sites, and more. Click here to learn more about their summer!
The annual EIPM/Meyer Cancer Center Summer Program recently concluded, and we'd like to congratulate all of the participants including Mayar and Nora from Hunter College (right), as well as the program coordinators, mentors and faculty who again gave so generously of their time!
I hope you enjoy reading about our recent departmental accomplishments, including new awards, media coverage of our work, participation in major conferences & meetings, and impressive publications by a range of EIPM colleagues.
Thank you again for your continued hard work and dedication to our mission.
Sincerely,
Olivier Elemento, Ph.D.
News Coverage & Awards
"Olivier Elemento’s Vision for Mainstreaming Precision Medicine," was published by Cure on August 5th. 
Our Chief Research Officer Dr. Bishoy Faltas provided the Expert Commentary, "The Effect of GLP1R Agonists on Bladder, Kidney, and Prostate Cancer Risk," to UroToday on August 1st.
New research in JAMA Oncology by Dr. Nasser Altorki and colleagues was covered in an August 8th ASCO Post article, "Visceral Pleural Invasion and Recurrence Risk in Patients Undergoing Surgery for NSCLC." And MedScape covered the same research in their August 22nd article "Does Pleural Invasion Lead to Worse Outcomes in Early NSCLC?"
Events
Our colleague Dr. Iman Hajirasouliha spoke at the 8th annual metaSub Conference, presenting "Microbiome Benchmarking and a Core Modular Analysis Pipeline," on August 13th.
Dr. Elemento presented "Genomes, Avatars and AI: The Future of Personalized Medicine," at the NCI's Center for Cancer Research Bioinformatics Training and Education Program on August 8th.
Publications
"Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial Cancer," was published in Clinical Cancer Research by Clinical Director Dr. Cora N. Sternberg and Dr. Scott T. Tagawa on August 1st.
"Recurrence of Non–Small Cell Lung Cancer With Visceral Pleural InvasionA Seconday Analysis of a Randomized Clinical Trial," was published in JAMA Oncology on August 1st by Dr. Nasser Altorki and colleagues. 
"The First Virtual Human Global Summit: Prepublication Meeting Report." The report was published on August 14th and shares meeting insights about the state of the art for medical digital twins, provide motivating opportunities and identify key challenges along the path to improved health and wellness through virtual human models and personalized digital twins," and was co-authored by Dr. Olivier Elemento and published by the U.S. Department of Energy's Office of Scientific and Technical Information.
"Unveiling the impact of circulating tumor cells: Two decades of discovery and clinical advancements in solid tumors," was published in Critical Reviews in Oncology/Hematology on August 17th by Scientific Director Massimo Cristofanilli M.D.
"A roadmap to the molecular human linking multiomics with population traits and diabetes subtypes. The authors report on integrating 18 diverse deep molecular phenotyping (omics-) technologies applied to urine, blood, and saliva samples from 391 participants of the multiethnic diabetes Qatar Metabolomics Study of Diabetes." Nature Communications on August 19th by Dr. Karsten Suhre and colleagues.
"Epigenetic regulation of cancer," was published in The International Review of Cell and Molecular Biology in the August 2024 edition of the journal by Dr. Lorenzo Galluzzi. 
"Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial," was published in European Urology on August 22nd by Clinical Director Dr. Cora N. Sternberg and colleagues.
# # #